Comparison of Spironolactone and Spironolactone Plus Metformin in the Treatment of Polycystic Ovary Syndrome

The study from 2015 compared the effectiveness of spironolactone alone versus spironolactone combined with metformin in treating women with polycystic ovary syndrome (PCOS). It involved 37 patients, with 18 receiving only spironolactone and 19 receiving both medications. The treatments were found to significantly reduce hirsutism scores, but there was no significant difference between the two groups in terms of BMI, Ferriman-Gallwey scores, hormone levels, or insulin resistance. Additionally, 27% of patients on spironolactone experienced inter-menstrual vaginal bleeding. The small sample size limits the conclusiveness of the study, and further research with more participants is recommended.